Latest & greatest articles for corticosteroids

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on corticosteroids or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on corticosteroids and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for corticosteroids

121. In adults with lateral hip pain post Total Hip Replacement (THR) (anterior lateral approach), is physiotherapy more effective in reducing pain and improving function than corticosteroid injection?

In adults with lateral hip pain post Total Hip Replacement (THR) (anterior lateral approach), is physiotherapy more effective in reducing pain and improving function than corticosteroid injection? Getting Evidence into Clinical Practice: Musculoskeletal Research Facilitation Group (CAT Group) Date: February 2017 CAT Lead: Tandi Coetzee/Treena Larkin Date CAT completed: February 2017 Date CAT to review: February 2019 Email: Treena.Larkin@nhs.net Specific Question: In adults with lateral hip pain (...) post Total Hip Replacement (THR) (anterior lateral approach), is physiotherapy more effective in reducing pain and improving function than corticosteroid injection? Clinical bottom line Search results produced no studies comparing physiotherapy intervention and corticosteroid injection to improve pain or function in adults with lateral hip pain post THR. Current clinical practice should remain unchanged due to the lack of evidence. Why is this important? Lateral hip pain occurs in 4.4 % of post

2018 Public Health England

122. Corticosteroids for pneumonia. (Full text)

Corticosteroids for pneumonia. Pneumonia is a common and potentially serious illness. Corticosteroids have been suggested for the treatment of different types of infection, however their role in the treatment of pneumonia remains unclear. This is an update of a review published in 2011.To assess the efficacy and safety of corticosteroids in the treatment of pneumonia.We searched the Cochrane Acute Respiratory Infections Group's Specialised Register, CENTRAL, MEDLINE, Embase, and LILACS on 3 (...) March 2017, together with relevant conference proceedings and references of identified trials. We also searched three trials registers for ongoing and unpublished trials.We included randomised controlled trials (RCTs) that assessed systemic corticosteroid therapy, given as adjunct to antibiotic treatment, versus placebo or no corticosteroids for adults and children with pneumonia.We used standard methodological procedures expected by Cochrane. Two review authors independently assessed risk of bias

2017 Cochrane PubMed

123. A Retrospective Analysis of Corticosteroid Utilization Before Initiation of Biologic DMARDs Among Patients with Rheumatoid Arthritis in the United States (Full text)

A Retrospective Analysis of Corticosteroid Utilization Before Initiation of Biologic DMARDs Among Patients with Rheumatoid Arthritis in the United States Understanding the effects of corticosteroid utilization prior to initiation of biologic disease-modifying antirheumatic drugs (DMARDs) can inform decision-makers on the appropriate use of these medications. This study examined treatment patterns and associated burden of corticosteroid utilization before initiation of biologic DMARDs among (...) rheumatoid arthritis (RA) patients.A retrospective analysis was conducted of adult RA patients in the US MarketScan Database (2011-2015). The following patterns of corticosteroid utilization were analyzed: whether corticosteroids were used; duration of use (short/long duration defined as < or ≥ 3 months); and dosage (low as < 2.5, medium as 2.5 to < 7.5 and high as ≥ 7.5 mg/day). Effects of corticosteroid use on time to biologic DMARD initiation were examined using Cox proportional hazards models

2017 Rheumatology and therapy PubMed

124. Perioperative adjuvant corticosteroids for postoperative analgesia in knee arthroplasty (Full text)

Perioperative adjuvant corticosteroids for postoperative analgesia in knee arthroplasty Background and purpose - Immediate postoperative pain management offered in knee arthroplasty is suboptimal in up to one-third of patients resulting in high opiate consumption and delayed discharge. In this meta-analysis we investigate the analgesic effect and safety of perioperative adjuvant corticosteroids in knee arthroplasty. Methods - Databases Medline, Embase, and Central were searched for randomized (...) studies comparing the analgesic effect of adjuvant perioperative corticosteroids in knee arthroplasty. Our primary outcome was pain score at 24 hours postoperatively. Secondary outcomes included pain at 12, 48, and 72 hours, opiate consumption, postoperative nausea and vomiting, infection, and discharge time. Systemic (intravenous) and local (intra-articular) corticosteroids were analyzed separately. Results - 14 randomized controlled trials (1,396 knees) were included. Mean corticosteroid dosages

2017 EvidenceUpdates PubMed

125. High- vs Low-Dose Corticosteroid Injection in the Treatment of Adhesive Capsulitis with Severe Pain: A Randomized Controlled Double-Blind Study

High- vs Low-Dose Corticosteroid Injection in the Treatment of Adhesive Capsulitis with Severe Pain: A Randomized Controlled Double-Blind Study To compare the degree of pain relief between high-dose (40 mg of triamcinolone acetonide) and low-dose (20 mg of triamcinolone acetonide) corticosteroid injections in patients with severe pain due to adhesive capsulitis.A prospective, randomized, double-blind, dose-comparative study.A total of 32 patients who were diagnosed with adhesive capsulitis

2017 EvidenceUpdates

126. The risk of mycobacterial infections associated with inhaled corticosteroid use

The risk of mycobacterial infections associated with inhaled corticosteroid use Inhaled corticosteroid (ICS) use is associated with an increased risk of pneumonia. This study was performed to determine if ICS use is associated with an increased risk of nontuberculous mycobacterial pulmonary disease (NTM-PD) or tuberculosis (TB).We conducted a population-based nested case-control study using linked laboratory and health administrative databases in Ontario, Canada, including adults aged ≥66 years

2017 EvidenceUpdates

127. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. (Full text)

Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a progressive or relapsing and remitting paralysing illness, probably due to an autoimmune response, which should benefit from corticosteroid treatment. Non-randomised studies suggest that corticosteroids are beneficial. Two commonly used corticosteroids are prednisone and prednisolone. Both are usually given as oral tablets. Prednisone is converted (...) into prednisolone in the liver so that the effect of the two drugs is usually the same. Another corticosteroid, dexamethasone, is more potent and is used in smaller doses. The review was first published in 2001 and last updated in 2015; we undertook this update to identify any new evidence.To assess the effects of corticosteroid treatment for CIDP compared to placebo or no treatment, and to compare the effects of different corticosteroid regimens.On 8 November 2016, we searched the Cochrane Neuromuscular

2017 Cochrane PubMed

128. Guidelines for the Diagnosis and Management of Critical Illness-Related Corticosteroid Insufficiency (CIRCI) in Critically Ill Patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017 (Full text)

Guidelines for the Diagnosis and Management of Critical Illness-Related Corticosteroid Insufficiency (CIRCI) in Critically Ill Patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017 To update the 2008 consensus statements for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in adult and pediatric patients.A multispecialty task force of 16 international experts in critical care medicine (...) of evidence). We suggest not using corticosteroids in adult patients with sepsis without shock (conditional recommendation, moderate quality of evidence). We suggest the use of IV methylprednisolone 1 mg/kg/day in patients with early moderate to severe acute respiratory distress syndrome (PaO2/FiO2 < 200 and within 14 days of onset) (conditional, moderate quality of evidence). Corticosteroids are not suggested for patients with major trauma (conditional, low quality of evidence).Evidence-based

2017 EvidenceUpdates PubMed

129. Early corticosteroid therapy does not improve the prognosis of paediatric septic shock

Early corticosteroid therapy does not improve the prognosis of paediatric septic shock Early corticosteroid therapy does not improve the prognosis of paediatric septic shock - Evidencias en pediatría De Lucas García N, Esparza Olcina MJ. En pacientes pediátricos con shock séptico, el uso precoz de corticoides no mejora el pronóstico. Evid Pediatr. 2017;13:40. " /> Searching, please wait Show menu Library Management You did not add any article to your library yet. | Search Evidence-Based (...) decision making Evidence-Based decision making Show menu Library Management You did not add any article to your library yet. × User Password Log in × Reset password If you need to reset your password please enter your email and click the Send button. You will receive an email to complete the process. Email Send × Library Management × September 2017. Volume 13. Number 3 Early corticosteroid therapy does not improve the prognosis of paediatric septic shock Rating: 0 (0 Votes) Reviewers: , . | Newsletter

2017 Evidencias en Pediatría

130. Rotator Cuff Calcific Tendinitis: Ultrasound-Guided Needling and Lavage Versus Subacromial Corticosteroids: Five-Year Outcomes of a Randomized Controlled Trial

Rotator Cuff Calcific Tendinitis: Ultrasound-Guided Needling and Lavage Versus Subacromial Corticosteroids: Five-Year Outcomes of a Randomized Controlled Trial Barbotage (needling and lavage) is often applied in the treatment of calcific tendinitis of the rotator cuff (RCCT). In a previously published randomized controlled trial, we reported superior clinical and radiological 1-year outcomes for barbotage combined with a corticosteroid injection in the subacromial bursa (SAIC) compared

2017 EvidenceUpdates

131. Topical Corticosteroids Improve Healing Time in Patients with Aphthous Ulcers

Topical Corticosteroids Improve Healing Time in Patients with Aphthous Ulcers UTCAT3273, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Topical Corticosteroids Improve Healing Time in Patients with Aphthous Ulcers Clinical Question In patients with aphthous ulcers, does treatment with topical corticosteroids, as compared to a placebo, improve healing time of the ulcers? Clinical Bottom Line Patients treated (...) with topical corticosteroids show an improved ulcer healing time. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Staines/2015 8 studies/583 patients Systematic review of randomized trials Key results 5 of the 8 studies in which ulcer duration was evaluated found that application of topical corticosteroids decreased the time required for the ulcer to heal (P Evidence Search “recurrent” AND “aphthous

2017 UTHSCSA Dental School CAT Library

132. Late (&gt; 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. (Full text)

Late (> 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. Many preterm infants who survive go on to develop bronchopulmonary dysplasia, probably as the result of persistent inflammation in the lungs. Corticosteroids have powerful anti-inflammatory effects and have been used to treat individuals with established bronchopulmonary dysplasia. However, it is unclear whether any beneficial effects outweigh the adverse effects (...) of these drugs.To examine the relative benefits and adverse effects of late systemic postnatal corticosteroid treatment (> 7 days) for preterm infants with evolving or established bronchopulmonary dysplasia.For the 2017 update, we used the standard search strategy of Cochrane Neonatal to search the Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 1); MEDLINE via PubMed (January 2013 to 21 February 2017); Embase (January 2013 to 21 February 2017); and the Cumulative Index to Nursing

2017 Cochrane PubMed

133. Early (&lt; 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. (PubMed)

Early (< 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. Bronchopulmonary dysplasia remains a major problem in neonatal intensive care units. Persistent inflammation in the lungs is the most likely underlying pathogenesis. Corticosteroids have been used to prevent or treat bronchopulmonary dysplasia because of their potent anti-inflammatory effects.To examine the relative benefits and adverse effects of systemic postnatal (...) corticosteroids commenced within the first seven days of life for preterm infants at risk of developing bronchopulmonary dysplasia.For the 2017 update, we used the standard search strategy of Cochrane Neonatal to search the Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 1); MEDLINE via PubMed (January 2013 to 21 February 2017); Embase (January 2013 to 21 February 2017); and the Cumulative Index to Nursing and Allied Health Literature (CINAHL) (January 2013 to 21 February 2017). We also

2017 Cochrane

134. Inhaled versus systemic corticosteroids for preventing bronchopulmonary dysplasia in ventilated very low birth weight preterm neonates. (Full text)

Inhaled versus systemic corticosteroids for preventing bronchopulmonary dysplasia in ventilated very low birth weight preterm neonates. Bronchopulmonary dysplasia (BPD) remains an important cause of mortality and morbidity in preterm infants and inflammation plays a significant role in its pathogenesis. The use of inhaled corticosteroids may modulate the inflammatory process without concomitant high systemic steroid concentrations and less risk of adverse effects. This is an update of a review (...) published in 2012 (Shah 2012). We recently updated the related review on "Inhaled versus systemic corticosteroids for treating bronchopulmonary dysplasia in ventilated very low birth weight preterm neonates".To determine the effect of inhaled versus systemic corticosteroids started within the first 7 days of life on preventing death or BPD in ventilated very low birth weight infants.We used the standard search strategy of Cochrane Neonatal to search the Cochrane Central Register of Controlled Trials

2017 Cochrane PubMed

135. Inhaled versus systemic corticosteroids for the treatment of bronchopulmonary dysplasia in ventilated very low birth weight preterm infants. (Full text)

Inhaled versus systemic corticosteroids for the treatment of bronchopulmonary dysplasia in ventilated very low birth weight preterm infants. This is an update of a review published in 2012. A related review "Inhaled versus systemic corticosteroids for preventing bronchopulmonary dysplasia in ventilated very low birth weight preterm neonates" has been updated as well. Bronchopulmonary dysplasia (BPD) is a serious and common problem among very low birth weight infants, despite the use (...) of antenatal steroids and postnatal surfactant therapy to decrease the incidence and severity of respiratory distress syndrome. Due to their anti-inflammatory properties, corticosteroids have been widely used to treat or prevent BPD. However, the use of systemic steroids has been associated with serious short- and long-term adverse effects. Administration of corticosteroids topically through the respiratory tract may result in beneficial effects on the pulmonary system with fewer undesirable systemic side

2017 Cochrane PubMed

136. Long-Acting β-Agonists (LABA) Combined With Long-Acting Muscarinic Antagonists or LABA Combined With Inhaled Corticosteroids for Patients With Stable COPD. (PubMed)

Long-Acting β-Agonists (LABA) Combined With Long-Acting Muscarinic Antagonists or LABA Combined With Inhaled Corticosteroids for Patients With Stable COPD. Are inhaled long-acting muscarinic antagonists (LAMA) combined with long-acting β-agonists (LABA) associated with differences in the incidence of chronic obstructive pulmonary disease (COPD) exacerbation and serious adverse events and with differences in quality of life and forced expiratory volume in the first second of expiration (FEV1) vs (...) inhaled LABA plus inhaled corticosteroids therapy for the treatment of stable COPD?Compared with inhaled LABA combined with corticosteroids, inhaled LAMA combined with LABA may be associated with a lower risk of COPD exacerbation and with greater improvement in FEV1 without differences in the incidence of serious severe adverse events or quality of life.

2017 JAMA

137. Are intratympanic corticosteroids effective for Ménière’s disease? (Full text)

Are intratympanic corticosteroids effective for MénièreÂ’s disease? Ménière’s disease affects the inner ear and its main symptoms are vertigo, hearing loss and fluctuating aural symptoms. Nowadays, there are many therapeutic alternatives, being the use of intratympanic corticosteroids one that has become popular. To answer this question, we searched in Epistemonikos database, which is maintained by screening multiple databases. We identified four systematic reviews including 15 studies (...) overall, of which seven were randomized trials. We extracted data and generated a summary of findings table using the GRADE approach. We concluded intratympanic corticosteroids probably do not decrease tinnitus, and might not decrease vertigo, hearing loss or aural fullness sensation in Ménière’s disease. Intratympanic corticosteroids probably do not cause important adverse effects.

2017 Medwave PubMed

138. Antenatal corticosteroids for women at risk of imminent preterm birth in low-resource countries: the case for equipoise and the need for efficacy trials (Full text)

Antenatal corticosteroids for women at risk of imminent preterm birth in low-resource countries: the case for equipoise and the need for efficacy trials The scientific basis for antenatal corticosteroids (ACS) for women at risk of preterm birth has rapidly changed in recent years. Two landmark trials-the Antenatal Corticosteroid Trial and the Antenatal Late Preterm Steroids Trial-have challenged the long-held assumptions on the comparative health benefits and harms regarding the use of ACS

2017 BMJ global health PubMed

139. Corticosteroid Injection for the Treatment of Morton's Neuroma: A Prospective, Double-Blinded, Randomized, Placebo-Controlled Trial

Corticosteroid Injection for the Treatment of Morton's Neuroma: A Prospective, Double-Blinded, Randomized, Placebo-Controlled Trial The effectiveness of corticosteroid injection for the treatment of Morton's neuroma is unclear. In addition, most of the studies related to it are case-control or retrospective case series. The purpose of this study was to compare the effectiveness between corticosteroid injection associated with local anesthetic and local anesthetic alone (placebo control group (...) ) for the treatment of Morton's neuroma.Forty-one patients with a diagnosis of Morton's neuroma were randomized to receive 3 injections of either a corticosteroid plus a local anesthetic or a local anesthetic alone. The patients and the researcher who collected data were blinded to the treatment groups. The visual analog scale for pain and the American Orthopaedic Foot & Ankle Score (metatarsophalangeal/interphalangeal score) were obtained at baseline, after each injection, and at 3 and 6 months after the last

2017 EvidenceUpdates

140. Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration

Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration - GOV.UK GOV.UK uses cookies to make the site simpler. Search Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration Central serous chorioretinopathy is a retinal disorder that has been linked to the systemic use (...) of corticosteroids. Recently, it has also been reported after local administration of corticosteroids via inhaled and intranasal, epidural, intra-articular, topical dermal, and periocular routes. Published 15 August 2017 From: Therapeutic area: , , Contents Advice for healthcare professionals: advise patients to report any blurred vision or other visual disturbances during corticosteroid treatment consider referral to an ophthalmologist for evaluation of possible causes if a patient presents with vision problems

2017 MHRA Drug Safety Update